Product Data Sheet

Cas No.:	157115-85-0	Cat. No:	PL04722
Product Name:	Omberacetam		
Product synonym:	N-(1-(苯基乙酰基)-L-脯氨酰)甘氨酸乙酯;N-(1-(苯基乙酰基)-L-脯氨酰)甘氨酸乙酯(Noopept);Noopept（GVS-111） 抑制剂;苯乙酰甘氨酸乙酯;N-(1-(苯基乙酰基)-L-脯氨酰)甘氨酸乙酯生产厂家		
Chemical name:	Omberacetam		
MF:	C17H22N2O4	FW:	318.36758
Purity:	≥99%	Batch No.:	-
Storage:			
Structural formula:			
λmax：	-	Formulation：	-
Solubility :			
SMILES :	O=C(OCC)CNC([C@H]1N(C(CC2=CC=CC=C2)=O)CCC1)=O		
InChI Code:	-		
InChI Key:			
WARNING This product is not for human or veterinary use.			

Product Description

Omberacetam (GVS-111) 是可作为膳食补充剂的多肽。

生物活性	Omberacetam (GVS-111) is a medication promoted and prescribed in Russia and neighbouring countries as a nootropic.
体外研究(In Vitro)	Nooglutil exhibits pharmacologically significant competition with a selective agonist of AMPA receptors ([G-3H]Ro 48-8587) for the receptor binding sites (with IC50 = 6.4 +/- 0.2 microM), while the competition of noopept for these receptor binding sites was lower by an order of magnitude (IC50 = 80 +/- 5.6 microM) [1]. GVS-111 significantly increased neuronal survival after H(2)O(2)-treatment displaying a dose-dependent neuroprotective activity from 10 nM to 100 microM, and an IC(50) value of 1.21+/-0.07 microM. GVS-111 inhibited the accumulation of intracellular free radicals and lipid peroxidation damage in neurons treated with H(2)O(2) or FeSO(4), suggesting an antioxidant mechanism of action [2]. has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究(In Vivo)	N-Phenylacetyl-L-prolylglycine ethyl ester (GVS-111) administered intravenously at a dose of 0.5 mg/kg/day, for the first time 1 h after ischaemic lesion and then for 9 post-operative days, with the last administration 15 min before testing, attenuated the deficit [3]. GVS-111 itself was not found in rat brain 1 h after 5 mg/kg i.p. administration up to limit of detection (LOD) under high performance liquid chromatography (HPLC) conditions [4]. The most pronounced antiinflammatory effect of dipeptide was observed on the model of adjuvant arthritis in rats, where the drug administered over 25 days in a daily dose of 0.5 mg/kg (i.m.) or 5 mg/kg (p.o.) significantly reduced the chronic immune inflammation (on the 12th day, by 94.0 and 74.1%, respectively) [5]. has not independently confirmed the accuracy of these methods.
包装储存	Powder -20°C 3 years；4°C 2 years
溶解度数据	In Vitro: DMSO : ≥ 100 mg/mL (314.10 mM)配制储备液